LLY

1,014.11

-2.29%↓

JNJ

202.6

-1.25%↓

ABBV

228.53

-0.44%↓

UNH

331.72

-2.21%↓

AZN

90.3

-0.56%↓

LLY

1,014.11

-2.29%↓

JNJ

202.6

-1.25%↓

ABBV

228.53

-0.44%↓

UNH

331.72

-2.21%↓

AZN

90.3

-0.56%↓

LLY

1,014.11

-2.29%↓

JNJ

202.6

-1.25%↓

ABBV

228.53

-0.44%↓

UNH

331.72

-2.21%↓

AZN

90.3

-0.56%↓

LLY

1,014.11

-2.29%↓

JNJ

202.6

-1.25%↓

ABBV

228.53

-0.44%↓

UNH

331.72

-2.21%↓

AZN

90.3

-0.56%↓

LLY

1,014.11

-2.29%↓

JNJ

202.6

-1.25%↓

ABBV

228.53

-0.44%↓

UNH

331.72

-2.21%↓

AZN

90.3

-0.56%↓

Search

Twist Bioscience Corp

Открыт

СекторЗдравоохранение

32.6 5.26

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

30.42

Макс.

32.57

Ключевые показатели

By Trading Economics

Доход

-48M

-27M

Продажи

3M

99M

Прибыль на акцию

-0.45

Рентабельность продаж

-27.41

Сотрудники

979

EBITDA

-2.3M

-26M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+27.26% upside

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-43M

1.8B

Предыдущая цена открытия

27.34

Предыдущая цена закрытия

32.6

Новостные настроения

By Acuity

50%

50%

167 / 374 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Very Strong Bearish Evidence

Twist Bioscience Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

3 дек. 2025 г., 23:21 UTC

Отчет
Приобретения, слияния, поглощения

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3 дек. 2025 г., 23:14 UTC

Приобретения, слияния, поглощения

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3 дек. 2025 г., 22:01 UTC

Главные движущие силы рынка

Costco Wholesale Reports Higher Monthly Sales

3 дек. 2025 г., 21:38 UTC

Отчет

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3 дек. 2025 г., 23:59 UTC

Обсуждения рынка

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3 дек. 2025 г., 23:49 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

3 дек. 2025 г., 23:49 UTC

Обсуждения рынка

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3 дек. 2025 г., 23:49 UTC

Обсуждения рынка

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3 дек. 2025 г., 23:13 UTC

Обсуждения рынка

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3 дек. 2025 г., 23:10 UTC

Отчет

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3 дек. 2025 г., 23:08 UTC

Обсуждения рынка

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3 дек. 2025 г., 23:06 UTC

Приобретения, слияния, поглощения

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3 дек. 2025 г., 22:59 UTC

Приобретения, слияния, поглощения

EQB to Buy PC Financial From Loblaw for About $573.5M

3 дек. 2025 г., 22:45 UTC

Обсуждения рынка

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3 дек. 2025 г., 22:20 UTC

Отчет

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3 дек. 2025 г., 22:19 UTC

Отчет

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3 дек. 2025 г., 22:17 UTC

Отчет

Salesforce Working to Add Voice to Agentforce, CEO Says

3 дек. 2025 г., 22:16 UTC

Отчет

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3 дек. 2025 г., 22:15 UTC

Отчет

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3 дек. 2025 г., 22:10 UTC

Приобретения, слияния, поглощения

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3 дек. 2025 г., 22:09 UTC

Приобретения, слияния, поглощения

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3 дек. 2025 г., 21:50 UTC

Обсуждения рынка

Auto & Transport Roundup: Market Talk

3 дек. 2025 г., 21:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

3 дек. 2025 г., 21:49 UTC

Отчет

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 дек. 2025 г., 21:23 UTC

Отчет

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3 дек. 2025 г., 21:19 UTC

Отчет

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 дек. 2025 г., 21:06 UTC

Отчет

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3 дек. 2025 г., 21:04 UTC

Отчет

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3 дек. 2025 г., 21:04 UTC

Отчет

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3 дек. 2025 г., 21:03 UTC

Отчет

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Сравнение c конкурентами

Изменение цены

Twist Bioscience Corp Прогноз

Целевая цена

By TipRanks

27.26% рост

Прогноз на 12 месяцев

Средняя 38 USD  27.26%

Максимум 42 USD

Минимум 32 USD

Основано на мнении 5 аналитиков Wall Street, спрогнозировавших целевые цены для Twist Bioscience Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

5 ratings

5

Покупка

0

Удержание

0

Продажа

Техническая оценка

By Trading Central

31.56 / 38.6884Поддержка и Сопротивление

Краткосрочная

Very Strong Bearish Evidence

Среднесрочная

Bearish Evidence

Долгосрочная

Bearish Evidence

Настроения

By Acuity

167 / 374Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Средняя

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat